USNAUSANA HEALTH SCIENCES INC
Medicinal Chemicals & Botanical Products
- Revenue
- $925M
- 8.3% YoY
- Operating margin
- 4.0%
- 48% YoY
- EBITDA
- $70M
- 13% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear208% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowFired123% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear16% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2026 | YoY |
|---|---|---|---|---|---|
| Revenue | $999M | $921M | $855M | $925M | 8.3% |
| Operating income | $108M | $93M | $66M | $37M | 44% |
| Net income | $117M | $64M | $42M | $11M | 74% |
| Operating cash flow | $104M | $71M | $61M | $22M | 63% |
| Capex | $10M | $14M | $10M | $14M | 37% |
| Stock-based comp | $13M | $15M | $15M | $14M | 5.0% |
| Buybacks | $25M | $12M | $9M | $28M | 191% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2026 | — | — | 25 | 49 |
| FY2024 | — | — | 46 | 94 |
| FY2023 | — | — | 70 | 47 |
| FY2022 | — | — | 131 | 97 |